Y. Matsuo

Oral valganciclovir as preemptive therapy is effective for cytomegalovirus infection in allogeneic hematopoietic stem cell transplant recipients

K. Akashi, K. Takenaka, T. Miyamoto, 2009, International journal of hematology.

The Confirmation of Safety for the Intensified Conditioning Regimens: A Retrospective Study of Allogeneic Hematopoietic Stem Cell Transplantation for Non-Remission Hematological Malignant Diseases

T. Iino, H. Henzan, N. Saito, 2018, International journal of hematology-oncology and stem cell research.

Encephalomyelitis mimicking multiple sclerosis associated with chronic graft-versus-host disease after allogeneic bone marrow transplantation.

K. Akashi, H. Iwasaki, K. Takenaka, 2009, Internal medicine.

Incidence and predictors of recurrent sick leave in survivors who returned to work after allogeneic hematopoietic cell transplantation

S. Kako, Takuhiro Yamaguchi, N. Uoshima, 2022, Journal of Cancer Survivorship.

The impact of hepatitis B core antibody levels on HBV reactivation after allogeneic hematopoietic SCT: an 11-year experience at a single center

H. Henzan, N. Saito, S. Yoshida, 2016, Bone Marrow Transplantation.

Toxoplasmosis encephalitis following severe graft‐vs.‐host disease after allogeneic hematopoietic stem cell transplantation: 17 yr experience in Fukuoka BMT group

K. Takenaka, T. Miyamoto, Y. Kunisaki, 2007, European journal of haematology.

HBV reactivation after hematopoietic stem cell transplantation and rituximab-containing chemotherapy: a 12-year experience at a single center

Kazuhiro Takahashi, H. Henzan, N. Saito, 2018, Bone Marrow Transplantation.

Outcomes of allogeneic stem cell transplantation for patients with hematologic diseases ≥60 years old

T. Shima, T. Eto, T. Kuriyama, 2023, Blood cell therapy.

Risk factors and outcome of Stenotrophomonas maltophilia infection after allogeneic hematopoietic stem cell transplantation: JSTCT, Transplant Complications Working Group.

Y. Kanda, Y. Mori, Takafumi Kimura, 2023, Annals of hematology.